Kairos Pharma, Ltd. (KAPA) Stock Analysis

Kairos Pharma, Ltd. (KAPA) is a publicly traded company in the HEALTHCARE sector. It trades at $0.47, carries a market capitalization of $10.58M. This page summarizes the public market data, fundamentals, and frequently asked questions for KAPA, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NYSE MKT

Key Metrics

• Price: $0.47
• Market Cap: $10.58M
• EPS: $-0.30
• 52-Week High: $2.11
• 52-Week Low: $0.42

Market Sentiment

Kairos Pharma, Ltd. currently has a Neutral sentiment score of 0.02.

About Kairos Pharma, Ltd.

Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical firm headquartered in Los Angeles, California, that is focused on developing innovative therapeutic solutions for cancer. The company boasts a diversified pipeline of proprietary drug candidates targeting significant unmet medical needs within oncology, demonstrating its commitment to enhancing patient outcomes. With its strong emphasis on research and development, Kairos is well-positioned to navigate the competitive biopharmac...

GNG Research Analysis

GNG Research scores Kairos Pharma, Ltd. (KAPA) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for KAPA.

Frequently Asked Questions

Does KAPA pay dividends?

Kairos Pharma, Ltd. (KAPA) does not currently pay a regular dividend.

What is KAPA's market cap?

Kairos Pharma, Ltd. (KAPA) has a market capitalization of $10.58M with a current stock price of $0.47.